BioLife Solutions Inc (NASDAQ:BLFS) CRO James Mathers sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $16.05, for a total value of $40,125.00. Following the transaction, the executive now owns 19,884 shares of the company’s stock, valued at $319,138.20. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

James Mathers also recently made the following trade(s):

  • On Tuesday, December 10th, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $15.65, for a total value of $39,125.00.
  • On Thursday, December 12th, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $15.00, for a total value of $37,500.00.
  • On Wednesday, November 27th, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $16.27, for a total value of $40,675.00.
  • On Friday, November 29th, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $16.33, for a total value of $40,825.00.
  • On Tuesday, November 12th, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $16.69, for a total value of $41,725.00.
  • On Thursday, October 31st, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $16.89, for a total value of $42,225.00.
  • On Tuesday, October 29th, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $17.31, for a total value of $43,275.00.
  • On Tuesday, October 15th, James Mathers sold 2,500 shares of BioLife Solutions stock. The stock was sold at an average price of $16.06, for a total value of $40,150.00.
  • On Thursday, October 17th, James Mathers sold 2,693 shares of BioLife Solutions stock. The stock was sold at an average price of $16.42, for a total value of $44,219.06.

NASDAQ:BLFS opened at $17.03 on Friday. The stock’s fifty day moving average is $16.19 and its 200 day moving average is $17.33. BioLife Solutions Inc has a fifty-two week low of $11.60 and a fifty-two week high of $22.44. The firm has a market capitalization of $343.60 million, a PE ratio of 121.64, a PEG ratio of 12.22 and a beta of 1.24. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.33 and a current ratio of 6.49.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings data on Tuesday, November 12th. The medical equipment provider reported $0.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.01. BioLife Solutions had a return on equity of 5.37% and a net margin of 46.77%. The company had revenue of $6.60 million for the quarter, compared to the consensus estimate of $7.65 million. Equities analysts forecast that BioLife Solutions Inc will post 0.05 EPS for the current year.

BLFS has been the subject of a number of research reports. Stephens initiated coverage on BioLife Solutions in a research report on Tuesday. They set an “overweight” rating and a $23.00 target price for the company. TheStreet upgraded BioLife Solutions from a “c” rating to a “b-” rating in a research report on Friday, November 29th. ValuEngine upgraded BioLife Solutions from a “sell” rating to a “hold” rating in a research report on Tuesday, December 24th. Oppenheimer initiated coverage on BioLife Solutions in a research report on Wednesday, November 20th. They set an “outperform” rating and a $22.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $26.00 target price (up from $23.00) on shares of BioLife Solutions in a research report on Monday, December 16th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $22.50.

A number of hedge funds have recently modified their holdings of the stock. Alpine Woods Capital Investors LLC boosted its holdings in BioLife Solutions by 9.0% in the third quarter. Alpine Woods Capital Investors LLC now owns 10,900 shares of the medical equipment provider’s stock worth $181,000 after acquiring an additional 900 shares in the last quarter. Morgan Stanley boosted its holdings in BioLife Solutions by 17.5% in the second quarter. Morgan Stanley now owns 11,506 shares of the medical equipment provider’s stock worth $195,000 after acquiring an additional 1,713 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in BioLife Solutions in the second quarter worth about $30,000. Invesco Ltd. boosted its holdings in BioLife Solutions by 4.7% in the second quarter. Invesco Ltd. now owns 81,319 shares of the medical equipment provider’s stock worth $1,378,000 after acquiring an additional 3,669 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in BioLife Solutions by 9.9% in the second quarter. Northern Trust Corp now owns 50,959 shares of the medical equipment provider’s stock worth $863,000 after acquiring an additional 4,600 shares in the last quarter. 50.16% of the stock is currently owned by institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Recommended Story: How does the Beige Book influence monetary policy?

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.